Transcriptome and histone epigenome of Plasmodium vivax salivary-gland sporozoites point to tight regulatory control and mechanisms for liver-stage differentiation in relapsing malaria.
Aaron Jex, Ivo Mueller, Stefan Kappe, Sebastian Mikolajczak, Jetsumon Sattabongkot, Rapatbhorn Patrapuvich, Scott Lindner, Erika Flannery, Cristian Koepfli, Brendan Ansell, Anita Lerch, Samantha Emery, Sarah Charnaud, Jeffrey Smith, Nicholas Merrienne, Kristian Swearingen, Robert Moritz, Michaela Petter, M Duffy, Veruda Chuenchob
International Journal for Parasitology | Elsevier | Published : 2019
Plasmodium vivax is the key obstacle to malaria elimination in Asia and Latin America, largely attributed to its ability to form resilient hypnozoites (sleeper cells) in the host liver that escape treatment and cause relapsing infections. The decision to form hypnozoites is made early in the liver infection and may already be set in sporozoites prior to invasion. To better understand these early stages of infection, we undertook a comprehensive transcriptomic and histone epigenetic characterization of P. vivax sporozoites. Through comparisons with recently published proteomic data for the P. vivax sporozoite, our study found that although highly transcribed, transcripts associated with funct..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council (NHMRC, Australia)
Awarded by US Department of Defense
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The authors acknowledge funding from the National Health and Medical Research Council (NHMRC, Australia; APP1021544, 1043345 and 1092789), the Australian Research Council (ARC), the Victorian State Government Operational Infrastructure Support, Australia and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme, the Ian Potter Foundation, Australia the National Institute of Health, USA, the Bill and Melinda Gates Foundation, USA, the US Department of Defense (W81XWH-15-1-0249) and the Office of the Assistant Secretary of Defence for Health Affairs (USA) through the Peer Reviewed Medical Research Program (PRMRP).